S-1: Applied DNA Sciences Files for Resale of 41.6 Million Shares Following Warrant Issuance

Applied DNA Sciences is registering for resale up to 41.6 million shares of common stock issuable upon the exercise of outstanding warrants held by selling stockholders.

Summary

• Applied DNA Sciences has filed a registration statement for the resale of up to 41,640,625 shares of common stock.
• These shares are issuable upon the exercise of outstanding warrants, including 20,312,500 Series C Warrants, 20,312,500 Series D Warrants, and 1,015,625 Placement Agent Warrants.
• The warrants were issued in a private placement concurrent with a registered direct offering of common stock and pre-funded warrants.
• The exercise price for all warrants is $0.32 per share.
• The Series C Warrants become exercisable upon stockholder approval and expire five years after that date.
• The Series D Warrants become exercisable upon stockholder approval and expire 18 months after that date.
• The Placement Agent Warrants become exercisable upon stockholder approval and expire on October 30, 2029.
• The company will not receive any proceeds from the resale of the common stock by the selling stockholders, but will receive proceeds from any cash exercise of the warrants.
• The company intends to use the proceeds from any cash exercise of the warrants for the further development of its Therapeutic DNA Production Services, working capital, and general corporate purposes.
• As of November 15, 2024, the last reported sale price of the company's common stock was $0.16 per share.

Sentiment

Score: 3

Explanation: The document contains several negative indicators, including a low stock price, a Nasdaq deficiency notice, and concerns about the company's ability to continue as a going concern. While there are potential positives, such as the development of new technologies, the overall sentiment is negative.

Positives

• The potential for the company to receive up to $13.3 million in proceeds if all warrants are exercised for cash.
• The funds from warrant exercises will be used to further develop the Therapeutic DNA Production Services, which is a key growth area for the company.
• The company has a clear plan for the use of proceeds, focusing on strategic growth initiatives.

Negatives

• The company will not receive any proceeds from the resale of the common stock by the selling stockholders.
• The exercisability of the warrants is contingent upon obtaining stockholder approval.
• The company's stock price is currently trading at $0.16 per share, significantly below the warrant exercise price of $0.32.
• There is no guarantee that the warrants will be exercised for cash, as they can be exercised on a cashless basis.

Risks

• The company may not successfully implement its business strategies, including achieving its growth objectives.
• The company may modify and refine its business strategy, including possible divestitures or closings.
• Stockholders may suffer substantial dilution if certain provisions in the May 2024 Series Warrants or Series D Warrants are utilized.
• The exercisability of the Private Placement Warrants is contingent upon the company obtaining Warrant Stockholder Approval.
• There is substantial doubt relating to the company's ability to continue as a going concern.
• The company has received written notice from Nasdaq that it is not in compliance with Nasdaq's minimum bid price requirements and could be delisted.
• There is no assurance that a commercial demand for the company's Linea Mpox Virus Assay and/or mpox testing services will develop.

Future Outlook

The company intends to use the net proceeds from any cash exercise of the Private Placement Warrants for the further development of its Therapeutic DNA Production Services, as well as for working capital and general corporate purposes.

Management Comments

• The Companys management is currently engaged in a strategic review of the Companys business segments that may result in the closure or divestiture of the Companys MDx Testing Services and/or DNA Tagging and Security Products and Services, as well as workforce reductions and potential management changes.
• We expect that based on available opportunities and our beliefs regarding future opportunities, we will continue to modify and refine our business strategy.

Industry Context

The document highlights the company's focus on the growing market for nucleic acid-based therapeutics, particularly mRNA therapies, and its efforts to capitalize on this trend through its Linea DNA and Linea IVT platforms. The company also addresses the demand for product traceability in supply chains, particularly for cotton, due to regulations like the Uyghur Forced Labor Prevention Act.

Comparison to Industry Standards

• The document mentions that as of the third quarter of calendar year 2024, there were 4,099 gene, cell and RNA therapies in development, almost all of which use DNA in their manufacturing process, indicating a large market opportunity for the company's Linea DNA platform.
• The document also notes that as of the third quarter of calendar 2024, there were over 450 mRNA therapies under development, with the majority in the preclinical stage, highlighting the growth potential for the company's Linea IVT platform.
• The company's Linea DNA platform is positioned as an alternative to plasmid-based DNA manufacturing, which has been the standard for the past 40 years, suggesting a potential disruption in the market.
• The company's Linea IVT platform, which combines its Linea DNA IVT templates with its Linea RNAP, is aimed at improving mRNA production by reducing dsRNA contamination and shortening manufacturing times, which are key challenges in the industry.

Related Party Transactions

• The Selling Stockholders have had material relationships with the company within the past three years, including participation in previous offerings and placement agency agreements.

Stakeholder Impact

• Shareholders face potential dilution from the exercise of warrants and the potential for a reverse stock split.
• Employees may be affected by potential workforce reductions as part of a strategic review of the company's business segments.
• Customers of the company's Therapeutic DNA Production Services may benefit from the company's continued development of these technologies.
• Creditors may be concerned about the company's ability to continue as a going concern.

Next Steps

• The company needs to obtain stockholder approval for the warrants to become exercisable.
• The company intends to implement a reverse stock split to regain compliance with Nasdaq's minimum bid price rule.
• The company plans to further develop its Therapeutic DNA Production Services.
• The company will continue to seek to raise additional working capital through public equity, private equity or debt financings.

Key Dates

Keywords

warrants, common stock, resale, Therapeutic DNA Production Services, private placement, stockholder approval, Nasdaq, dilution, going concern, minimum bid price